Despite improvements in the diagnosis and management of lymphomas, many patients remain incurable with available treatments. advances in preclinical research and a better understanding of the molecular biology of lymphomas have allowed the development of a high number of therapeutic agents with innovative mechanisms of action. Many of these new agents have shown activity in patients not responding to standard treatments and there is optimism that their incorporation into the standard of care can result in improved treatment outcomes. Here we review new monoclonal antibodies and small molecules that have recently entered clinical evaluation for patients with lymphomas.